BRITANNIA LIFE SCIENCES Net Assets
BRITANNIA LIFE SCIENCES net assets. Based on the latest financial reports, BRITANNIA LIFE SCIENCES (L020) has net assets worth €17.23 Million EUR (≈ $20.14 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€22.06 Million ≈ $25.79 Million USD) and total liabilities (€4.83 Million ≈ $5.65 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore BRITANNIA LIFE SCIENCES (L020) net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €17.23 Million |
| % of Total Assets | 78.1% |
| Annual Growth Rate | 4.74% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 60.26 |
Net Assets of BRITANNIA LIFE SCIENCES (2022–2025)
Net assets of BRITANNIA LIFE SCIENCES from 2022 to 2025. This chart illustrates how BRITANNIA LIFE SCIENCES's net assets have evolved over time, based on quarterly financial data. See L020 net asset quality score to measure how much of total assets are equity-financed.
Annual Net Assets for BRITANNIA LIFE SCIENCES (2022–2025)
The table below shows the annual net assets of BRITANNIA LIFE SCIENCES from 2022 to 2025. For live market cap and overall valuation, see market cap of BRITANNIA LIFE SCIENCES.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | €6.30 Million ≈ $7.37 Million |
-5.54% |
| 2024-03-31 | €6.67 Million ≈ $7.80 Million |
-39.70% |
| 2023-03-31 | €11.06 Million ≈ $12.93 Million |
+101.75% |
| 2022-03-31 | €5.48 Million ≈ $6.41 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to BRITANNIA LIFE SCIENCES's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 290824000.0% over the analyzed period, indicating profitable operations and earnings retention.
BRITANNIA LIFE SCIENCES Net Assets Breakdown (March 2025)
BRITANNIA LIFE SCIENCES net assets breakdown by equity component as of March 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €19.59 Million | 310.91% |
| Total Equity | €6.30 Million | 100.00% |
BRITANNIA LIFE SCIENCES Competitors by Market Cap
The table below lists competitors of BRITANNIA LIFE SCIENCES ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PT Sunter Lakeside Hotel Tbk
JK:SNLK
|
$5.70 Million |
|
Basel Medical Group Ltd Ordinary Shares
NASDAQ:BMGL
|
$5.70 Million |
|
Hanwha Corp. Pfd. Series 1
KO:000885
|
$5.70 Million |
|
Jiankun International Bhd
KLSE:8923
|
$5.70 Million |
|
FIRST LITHIUM MINERALS
F:X28
|
$5.69 Million |
|
Firebrick Pharma Ltd
AU:FRE
|
$5.69 Million |
|
Utilico Emerging Markets Ltd
LSE:UEM
|
$5.69 Million |
|
E Investment & Development
KO:093230
|
$5.69 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BRITANNIA LIFE SCIENCES's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,437,821 to 6,300,779, a change of 3,862,958 (158.5%).
- Net income of 7,392,795 contributed positively to equity growth.
- Other factors decreased equity by 3,529,837.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €7.39 Million | +117.33% |
| Other Changes | €-3.53 Million | -56.02% |
| Total Change | €- | 158.46% |
Book Value vs Market Value Analysis
This analysis compares BRITANNIA LIFE SCIENCES's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.77x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 3.59x to 0.77x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-03-31 | €0.01 | €0.03 | x |
| 2023-03-31 | €0.04 | €0.03 | x |
| 2024-03-31 | €0.02 | €0.03 | x |
| 2025-03-31 | €0.04 | €0.03 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BRITANNIA LIFE SCIENCES utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 117.33%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2001.95%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 1.84x
- Recent ROE (117.33%) is above the historical average (-287.20%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -1142.96% | -211.76% | 0.35x | 15.59x | €-15.59 Million |
| 2023 | 72.39% | 79.39% | 0.27x | 3.35x | €4.38 Million |
| 2024 | -195.58% | -922.51% | 0.02x | 9.13x | €-5.01 Million |
| 2025 | 117.33% | 2001.95% | 0.03x | 1.84x | €6.76 Million |
Industry Comparison
This section compares BRITANNIA LIFE SCIENCES's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $165,369,067
- Average return on equity (ROE) among peers: -55.63%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BRITANNIA LIFE SCIENCES (L020) | €17.23 Million | -1142.96% | 0.28x | $5.69 Million |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $4.50 Million | -321.01% | 1.17x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $88.56 Million | -31.35% | 0.90x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $41.28 Million | -56.73% | 0.18x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $-51.59 Million | 0.00% | 0.00x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $715.33 Million | -51.14% | 0.23x | $141.97 Million |
| PreveCeutical Medical Inc (18H) | $-4.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $63.37 Million | -33.73% | 0.67x | $41.67 Billion |
| GH RESEARCH PLC DL-025 (1KA) | $277.18 Million | -3.32% | 0.01x | $1.22 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $714.18 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
About BRITANNIA LIFE SCIENCES
Britannia Life Sciences Inc. engages in the product testing, safety assessment, and manufacturing services in the United Kingdom and internationally. It serves cosmetics, consumer packaged and household goods, and nutraceutical industries. The company is headquartered in Toronto, Canada.